BFH772 (VEGFR2 inhibitor): Technical Guidance for Research Workflows

What This Product Solves

BFH772 (CAS 890128-81-1) is engineered as a potent small-molecule VEGFR2 inhibitor for research applications targeting the vascular endothelial growth factor receptor 2 (VEGFR2) signaling pathway. Its nanomolar IC50 (3 nM) and strong selectivity profile make it suitable for experiments requiring precise modulation of VEGFR2-driven angiogenesis, such as in tumor xenograft, in vivo angiogenesis models, or pathway-specific cellular assays. Unlike broad kinase inhibitors, BFH772 minimizes off-target effects, enabling focused investigation of VEGFR2-mediated mechanisms without confounding interference from related kinases such as FLT-1, FLT-4, or B-RAF. The compound is not suitable for workflows demanding aqueous solubility or broad-spectrum kinase inhibition, as it is insoluble in water and exhibits much lower efficacy against non-VEGFR2 targets. For full product specifications and documentation, see the BFH772 (VEGFR2 inhibitor) page.

Protocol Parameters

• Assay: VEGFR2 kinase inhibition
  Value: IC50 = 3 nM
  Applicability: Use in kinase assays or cell-based models focused on VEGFR2 pathway inhibition.
  Rationale: Enables quantitative assessment of VEGFR2 activity suppression in angiogenesis and tumor studies.
  Source type: Product dossier
• Assay: Solubility (organic solvents)
  Value: ≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in ethanol
  Applicability: Suitable for workflows using DMSO or ethanol as vehicles in in vitro and in vivo models.
  Rationale: Ensures adequate compound delivery in protocols where water solubility is not required.
  Source type: Product dossier
• Assay: Storage conditions
  Value: Store at -20°C; avoid long-term storage of solutions
  Applicability: Required for maintaining compound integrity and reproducibility across experiments.
  Rationale: Prevents degradation and loss of potency during storage or repeated freeze-thaw cycles.
  Source type: Product dossier
• Assay: Purity (QC parameter)
  Value: >96% (lot-specific)
  Applicability: Ensures minimal batch-to-batch variation and reliable experimental outcomes.
  Rationale: High-purity standards reduce risk of interfering byproducts in sensitive assays.
  Source type: Product dossier

Workflow Setup and QC Checklist

Before integrating BFH772 into your angiogenesis or tumor model workflow, adhere to the following procedural guidance for reliable results:

1. Solvent selection: Prepare BFH772 stock solutions in DMSO or ethanol at concentrations appropriate for your assay, ensuring complete dissolution. Avoid attempts to dissolve in aqueous media, as the compound is water-insoluble.
2. Storage and handling: Maintain all lyophilized material at -20°C. Prepare fresh working solutions just prior to use. Discard any unused diluted solutions to avoid potency loss.
3. Vehicle controls: Include DMSO or ethanol-only controls in all experimental arms to account for vehicle effects.
4. Quality check: Confirm the supplied purity (>96%) via lot-specific certificate of analysis. Inspect for precipitate or discoloration prior to use.
5. Dosing accuracy: Use validated pipetting for microliter volumes due to the high potency of BFH772. Prepare serial dilutions to achieve precise final concentrations, mindful of the low nanomolar activity range.
6. Documentation: Retain all batch QC and safety data sheets supplied by APExBIO for institutional compliance and reproducibility.

For additional workflow-specific guidance, see the article BFH772 (VEGFR2 inhibitor): Technical Protocols & Workflow Use, which details setup for pathway-selective assays when water solubility is not required.

Common Failure Modes and Fixes

• Incomplete solubilization in vehicle: If undissolved material persists in DMSO or ethanol, gently vortex and, if needed, warm the solution to room temperature. Do not use water or aqueous buffers for dissolution, as BFH772 is insoluble in these.
• Loss of activity in stored solutions: BFH772 solutions degrade over time, especially at room temperature or with repeated freeze-thaw cycles. Always prepare fresh solutions and avoid storing aliquots long-term.
• Unexpected off-target effects: While BFH772 is highly selective for VEGFR2, confirm specificity in your assay by including appropriate kinase controls and comparing with vehicle-treated samples.
• Precipitation in biological media: If precipitation occurs upon dilution into culture media, verify that the final DMSO or ethanol concentration remains within acceptable limits for your cell system (usually ≤0.1–0.5%). Add the compound to media slowly with thorough mixing.
• Batch variability: If experimental variability is observed, check the lot-specific purity and documentation. Contact the supplier if discrepancies in appearance or performance are detected.

For detailed troubleshooting in tumor model workflows, refer to BFH772 (VEGFR2 inhibitor): Technical Guide for Angiogenesis Research, which addresses setup and selectivity considerations for in vivo studies.

Scope and Limitations

BFH772 is best suited to applications requiring selective inhibition of VEGFR2 signaling, including studies of tumor angiogenesis and related in vitro assays where high kinase selectivity and organic solvent compatibility are essential. Its specificity reduces off-target interactions, making it optimal for dissecting VEGFR2-driven pathways. However, it is not appropriate for protocols requiring:

• Water-soluble compounds (due to insolubility in aqueous media)
• Broad-spectrum kinase inhibition (shows markedly reduced activity against FLT-1, FLT-4, B-RAF, RET, TIE-2, and others)
• Long-term storage of stock or working solutions
• Applications where the vehicle (DMSO/ethanol) is incompatible with biological systems

For researchers seeking a selective VEGFR2 kinase inhibitor for angiogenesis research, BFH772 offers strong utility within these boundaries. Alternative agents should be considered if broader kinase inhibition or aqueous solubility is required.

Conclusion

BFH772 (VEGFR2 inhibitor) is a practical tool for targeted disruption of VEGFR2-mediated angiogenic signaling, supporting studies in tumor angiogenesis and VEGFR2 pathway modulation. Its high selectivity, nanomolar potency, and compatibility with organic solvents make it valuable in workflows where water solubility and broad-spectrum inhibition are not required. For detailed specifications or certificate of analysis, consult the BFH772 (VEGFR2 inhibitor) product page. Always follow best practices for solvent handling, storage, and quality control to ensure reproducible results in research settings.